779 reports of this reaction
3.9% of all METHOXY POLYETHYLENE GLYCOL EPOETIN BETA reports
#5 most reported adverse reaction
PRURITUS is the #5 most commonly reported adverse reaction for METHOXY POLYETHYLENE GLYCOL EPOETIN BETA, manufactured by Vifor (International) Inc.. There are 779 FDA adverse event reports linking METHOXY POLYETHYLENE GLYCOL EPOETIN BETA to PRURITUS. This represents approximately 3.9% of all 19,964 adverse event reports for this drug.
Patients taking METHOXY POLYETHYLENE GLYCOL EPOETIN BETA who experience pruritus should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PRURITUS is moderately reported among METHOXY POLYETHYLENE GLYCOL EPOETIN BETA users, representing a notable but not dominant share of adverse events.
In addition to pruritus, the following adverse reactions have been reported for METHOXY POLYETHYLENE GLYCOL EPOETIN BETA:
The following drugs have also been linked to pruritus in FDA adverse event reports:
PRURITUS has been reported as an adverse event in 779 FDA reports for METHOXY POLYETHYLENE GLYCOL EPOETIN BETA. This does not prove causation, but indicates an association observed in post-market surveillance data.
PRURITUS accounts for approximately 3.9% of all adverse event reports for METHOXY POLYETHYLENE GLYCOL EPOETIN BETA, making it a notable side effect.
If you experience pruritus while taking METHOXY POLYETHYLENE GLYCOL EPOETIN BETA, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.